References
- [1] Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079-1092.
- [2] Khan FM, Gerbi BJ. Treatment planning in radiation oncology. Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012.
- [3] Pan HY, Jiang J, Hoffman KE, et al. Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer. J Clin Oncol. 2018;36(18):1823-1830.
- [4] Mavroidis P, Komisopoulos G, Buckey C, et al. Radiobiological evaluation of prostate cancer IMRT and conformal-RT plans using different treatment protocols. Phys Med. 2017;40:33-41.
- [5] Luxton G, Hancock SL, Boyer AL. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2004;59(1):267-284.
- [6] Deb P, Fielding AL. Radiobiological model comparison of 3D conformal radiotherapy and IMRT plans for the treatment of prostate cancer. Australas Phys Eng Sci Med. 2009;32(2):51-61.
- [7] Mesbahi A, Rasouli N, Mohammadzadeh M, et al. Comparison of Radiobiological Models for Radiation Therapy Plans of Prostate Cancer: Three-dimensional Conformal versus Intensity Modulated Radiation Therapy. J Biomed Phys Eng. 2018;8(3):1-12.
- [8] Khan MI, Jiang R, Kiciak A, et al. Dosimetric and radiobiological characterizations of prostate intensity-modulated radiotherapy and volumetric-modulated arc therapy: A single-institution review of ninety cases. J Med Phys. 2016;41(3):162-168.
- [9] Chow J, Jiang R, Kiciak A. Dose-volume consistency and radiobiological characterization between prostate IMRT and VMAT plans. Int J Cancer Ther Oncol. 2016;4(4).
- [10] Chow JC, Jiang R, Kiciak A, Markel D. Dosimetric comparison between the prostate intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) plans using the planning target volume (PTV) dose–volume factor. J Radiother Pract. 2016;15(3):263-268.
- [11] Schreibmann E, Xing L. Feasibility study of beam orientation class-solutions for prostate IMRT. Med Phys. 2004;31(10):2863-2870.
- [12] Schreibmann E, Lahanas M, Xing L, et al. Multiobjective evolutionary optimization of the number of beams, their orientations and weights for intensity-modulated radiation therapy. Phys Med Biol. 2004;49(5):747-770.
- [13] Yang R, Dai J, Yang Y, et al. Beam orientation optimization for intensity-modulated radiation therapy using mixed integer programming. Phys Med Biol. 2006;51(15):3653-3666.
- [14] Yuan L, Ge Y, Lee WR, et al. Quantitative analysis of the factors which affect the interpatient organ-at-risk dose sparing variation in IMRT plans. Med Phys. 2012;39(11):6868-6878.
- [15] Wu B, Ricchetti F, Sanguineti G, et al. Patient geometry-driven information retrieval for IMRT treatment plan quality control. Med Phys. 2009;36(12):5497-5505.
- [16] Källman P, Agren A, Brahme A. Tumour and normal tissue responses to fractionated non-uniform dose delivery. Int J Radiat Biol. 1992;62(2):249-262.
- [17] Pollack A, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31(31):3860-3868.
- [18] Sanchez-Nieto B, Nahum AE. BIOPLAN: software for the biological evaluation of radiotherapy treatment plans. Med Dosim. 2000;25(2):71-76.
- [19] Hodapp N. The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT). Strahlenther Onkol. 2012;188(1):97-99.
- [20] Lee WR, Amin MB, Bruner DW, et al. A phase III randomized study of hypofractionated 3D-CRT/IMRT versus conventionally fractionated 3D-CRT/IMRT in patients with favorable-risk prostate cancer. Clinical Trial NCT00331773.
- [21] Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys. 2006;64(2):518-526.